Project Grant R43HL169127
Award Date
8/1/23
Completion Date
7/31/24
Dollars Obligated
$597K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Neuronoff Inc. (VNH8CLTF2X41)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $311,824 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nytricx, Inc. to develop an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a medical device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - three major complications affecting patients following endovascular arterial repair...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $321,363 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nucleusrx, Inc., a small business located in Cranbury, NJ. The purpose of this 1-year SBIR Phase 1 project is to develop and test Nucleusrx's virtual care platform and remote intervention tool for post-acute care heart failure (HF) patients transitioning from the hospital to home. The goal is...
This $999,998 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (HBNP), to treat resistant hypertension. The grantee, Antlia Bioscience, Inc., is developing an innovative method to extend the lifespan of HBNP in the blood while maintaining its ability to lower blood pressure without...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), awarded a $1,847,271 Project Grant to The Pennsylvania State University (Penn State) to develop a soft, stretchable, and tissue-like bioadhesive electronic device for the treatment of resistant hypertension. The 5-year project aims to create a minimally invasive device that can enable long-term, efficient, safe, and non-pharmacological neuromodulation therapies for...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The software tool will leverage physics-based modeling, artificial intelligence, and machine learning to simulate the acute...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), is funding the development and validation of a novel minimally invasive electrode strategy to better isolate the posterior tibial nerve and treat overactive bladder (OAB). The $628,012 grant, awarded on Sep 18, 2024 with a final completion date of Jun 30, 2029, will support the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,283,558 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to the Massachusetts Institute of Technology (MIT) for the development and demonstration of Multi-Electroplasmonic Nanoantenna Arrays (MENAS) to enable wireless, high-resolution transmembrane-level electrophysiological recording of cardiomyocyte action potentials. The four-year project, running from August 1, 2024 to July 31,...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $298,368 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program to Link Medical LLC, a for-profit limited liability company located in Chelsea, Michigan. The grant funding supports the development of a novel catheter-based technology to treat mitral valve regurgitation, a condition affecting millions of Americans. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $323,230 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Sirona Medical Technologies, Inc. The goal of this R61 phase project is to develop and validate hardware that will interface Sirona's proprietary catheter technologies with radiofrequency (RF) and pulsed field (PF) energy generator platforms. This will establish the signal parameters required for the safe and effective delivery of ablative...